Jan Stratmann

1.5k total citations · 1 hit paper
48 papers, 818 citations indexed

About

Jan Stratmann is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Jan Stratmann has authored 48 papers receiving a total of 818 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 11 papers in Epidemiology. Recurrent topics in Jan Stratmann's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (11 papers) and Acute Myeloid Leukemia Research (8 papers). Jan Stratmann is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (11 papers) and Acute Myeloid Leukemia Research (8 papers). Jan Stratmann collaborates with scholars based in Germany, United States and France. Jan Stratmann's co-authors include Nir Yogev, Ari Waisman, Thomas Münzel, Eberhard Schulz, Matthias Oelze, Swenja Schuhmacher, Helmut Jonuleit, Sabine Kossmann, Maike Knorr and Stephan Grabbe and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Jan Stratmann

41 papers receiving 807 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lysozyme M–Positive Monocytes Mediate Angiotensin II–Induced Arterial Hypertension and Vascular Dysfunction

2011 407 citations Jan Stratmann et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan Stratmann Germany	13	240	163	162	159	157	48	818
Sydney Benchetrit Israel	18	104 0.4×	116 0.7×	144 0.9×	245 1.5×	132 0.8×	89	1.4k
Kyung Hee Yi South Korea	15	270 1.1×	291 1.8×	43 0.3×	93 0.6×	76 0.5×	28	1.0k
Fatih Bulucu Türkiye	16	69 0.3×	95 0.6×	91 0.6×	114 0.7×	64 0.4×	52	688
Masahiro Eriguchi Japan	15	93 0.4×	53 0.3×	56 0.3×	214 1.3×	98 0.6×	60	780
Leslie A. Garrett United States	17	134 0.6×	67 0.4×	43 0.3×	223 1.4×	91 0.6×	38	1.1k
Arjan J. Kwakernaak Netherlands	19	59 0.2×	67 0.4×	153 0.9×	185 1.2×	77 0.5×	45	991
Shixiang Wang China	16	118 0.5×	40 0.2×	94 0.6×	91 0.6×	84 0.5×	60	801
Michelle Jankowski United States	16	126 0.5×	79 0.5×	28 0.2×	145 0.9×	249 1.6×	35	832
Mustafa Çakar Türkiye	16	154 0.6×	252 1.5×	28 0.2×	208 1.3×	94 0.6×	50	801
Fabiana Busti Italy	21	65 0.3×	53 0.3×	348 2.1×	89 0.6×	125 0.8×	47	1.3k

Countries citing papers authored by Jan Stratmann

Since Specialization

Citations

This map shows the geographic impact of Jan Stratmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Stratmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Stratmann more than expected).

Fields of papers citing papers by Jan Stratmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Stratmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Stratmann. The network helps show where Jan Stratmann may publish in the future.

Co-authorship network of co-authors of Jan Stratmann

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Stratmann. A scholar is included among the top collaborators of Jan Stratmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Stratmann. Jan Stratmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grohé, Christian, Jan Stratmann, Stefan Hammerschmidt, et al.. (2025). 1904P Real-world outcomes of nintedanib plus docetaxel for adenocarcinoma NSCLC after failure of first-line immunochemotherapy: The non-interventional VARGADO study. Annals of Oncology. 36. S1018–S1019.

Liu, Geoffrey, Todd M. Bauer, Enriqueta Felip, et al.. (2025). Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts. Lung Cancer. 206. 108662–108662.

Stratmann, Jan, Florestan Koll, Sebastian Wagner, et al.. (2024). Concepts of lines of therapy in cancer treatment: findings from an expert interview-based study. BMC Research Notes. 17(1). 137–137.

Mazières, Julien, M. Duruisseaux, Chigusa Morizane, et al.. (2023). 2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3. Annals of Oncology. 34. S1076–S1077. 1 indexed citations

Stratmann, Jan, Nikolaj Frost, Petros Christopoulos, et al.. (2023). 1405P Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany. Annals of Oncology. 34. S804–S804. 1 indexed citations

Wolf, Andrea, Jan Stratmann, Shabnam Shaid, et al.. (2023). Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018. BMC Pulmonary Medicine. 23(1). 16–16. 3 indexed citations

Koschade, Sebastian E., Kevin Klann, Shabnam Shaid, et al.. (2022). Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia. 36(10). 2396–2407. 19 indexed citations

Stratmann, Jan, Martin Sebastian, Maximilian Rauch, et al.. (2022). Pulmonary Resection after Radiosurgery and Neoadjuvant Immunochemotherapy for NSCLC Patients with Synchronous Brain Metastasis—A Case Series of Three Patients. Current Oncology. 29(4). 2225–2239. 1 indexed citations

Althoff, Friederike, et al.. (2022). Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib First-Line Treatment. Clinical Lung Cancer. 23(7). e473–e477. 6 indexed citations

10.

Büttner, Stefan, Jan Stratmann, Uta Brunnberg, et al.. (2021). Acute kidney injury adversely affects the clinical course of acute myeloid leukemia patients undergoing induction chemotherapy. Annals of Hematology. 100(5). 1159–1167. 6 indexed citations

11.

Koschade, Sebastian E., Stefan Büttner, Jan Stratmann, et al.. (2021). Fluid overload is associated with increased 90-day mortality in AML patients undergoing induction chemotherapy. Annals of Hematology. 100(10). 2603–2611. 3 indexed citations

12.

Himmelsbach, Vera, Mate Knabe, Kai‐Henrik Peiffer, et al.. (2021). Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology. 148(6). 1465–1472. 10 indexed citations

13.

Frost, Nikolaj, Diego Kauffmann‐Guerrero, Jan Stratmann, et al.. (2020). 1368P Lorlatinib in pretreated ALK/ROS1-positive non-small cell lung cancer (NSCLC): Results from the German early access program. Annals of Oncology. 31. S874–S874. 1 indexed citations

14.

Brunnberg, Uta, Jan Stratmann, Michael Hogardt, et al.. (2020). Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy. Annals of Hematology. 99(11). 2547–2553. 8 indexed citations

15.

Stratmann, Jan, et al.. (2019). Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy. PLoS ONE. 14(9). e0223013–e0223013. 7 indexed citations

16.

Stratmann, Jan, Christoph Rummelt, Sebastian E. Koschade, et al.. (2019). Low-dose melphalan in elderly patients with relapsed or refractory acute myeloid leukemia: A well-tolerated and effective treatment after hypomethylating-agent failure. Leukemia Research. 85. 106192–106192. 4 indexed citations

17.

Stratmann, Jan, Sebastian E. Koschade, Knut Wendelin, et al.. (2019). Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma. Annals of Hematology. 98(3). 647–656. 3 indexed citations

18.

Stratmann, Jan, Claudia Reinheimer, Michael Hogardt, et al.. (2019). Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy. PLoS ONE. 14(1). e0210991–e0210991. 44 indexed citations

19.

Hechtner, Marlene, Martin Eichler, Roland Buhl, et al.. (2018). Quality of Life in NSCLC Survivors — A Multicenter Cross-Sectional Study. Journal of Thoracic Oncology. 14(3). 420–435. 57 indexed citations

20.

Stratmann, Jan, et al.. (2017). P3.02b-110 ROS1 Translocation as a Bystander Mutation in T790M EGFR Mutated NSCLC. Journal of Thoracic Oncology. 12(1). S1260–S1260.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact